Sana Biotechnology, Inc.
SANA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.00 | 0.12 | -0.21 |
| FCF Yield | -5.07% | -12.22% | -12.36% | -5.71% |
| EV / EBITDA | -7.00 | -8.39 | -8.11 | -16.44 |
| Quality | ||||
| ROIC | -27.77% | -11.90% | -10.87% | -11.81% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 0.35 | 0.99 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 32.39% | -2.51% | 14.87% | 21.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | 0.10 | 0.77 | 0.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -71.51 | -24.39 | -61.37 | -66.35 |